Oric Pharmaceuticals (ORIC) to Release Quarterly Earnings on Tuesday

Oric Pharmaceuticals (NASDAQ:ORIC) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect Oric Pharmaceuticals to post earnings of ($0.33) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 17, 2026 at 11:30 AM ET.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.08. On average, analysts expect Oric Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oric Pharmaceuticals Stock Up 2.8%

ORIC stock opened at $10.71 on Tuesday. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -6.19 and a beta of 1.35. Oric Pharmaceuticals has a 52-week low of $3.90 and a 52-week high of $14.93. The stock’s fifty day simple moving average is $9.92 and its 200-day simple moving average is $10.89.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ORIC shares. Wells Fargo & Company raised their price target on Oric Pharmaceuticals from $19.00 to $25.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. Piper Sandler started coverage on shares of Oric Pharmaceuticals in a report on Wednesday, January 7th. They set an “overweight” rating and a $22.00 price objective on the stock. Wall Street Zen downgraded shares of Oric Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, November 23rd. Evercore started coverage on shares of Oric Pharmaceuticals in a research report on Thursday, November 20th. They set an “outperform” rating and a $25.00 price target for the company. Finally, Oppenheimer lifted their price target on shares of Oric Pharmaceuticals from $12.00 to $15.00 and gave the company an “outperform” rating in a report on Friday, November 14th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.90.

Insider Activity at Oric Pharmaceuticals

In other Oric Pharmaceuticals news, insider Pratik S. Multani sold 10,720 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total value of $97,123.20. Following the transaction, the insider directly owned 68,149 shares of the company’s stock, valued at $617,429.94. This trade represents a 13.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Dominic Piscitelli sold 10,720 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total value of $97,123.20. Following the transaction, the chief financial officer owned 68,148 shares in the company, valued at approximately $617,420.88. This represents a 13.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 54,814 shares of company stock worth $496,615. 5.55% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Oric Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new stake in Oric Pharmaceuticals in the third quarter valued at approximately $60,000. CANADA LIFE ASSURANCE Co acquired a new position in shares of Oric Pharmaceuticals during the third quarter worth $65,000. Creative Planning purchased a new position in shares of Oric Pharmaceuticals in the second quarter valued at $113,000. Tower Research Capital LLC TRC grew its holdings in Oric Pharmaceuticals by 1,293.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,757 shares of the company’s stock valued at $119,000 after purchasing an additional 10,913 shares in the last quarter. Finally, Jane Street Group LLC increased its stake in Oric Pharmaceuticals by 56.0% during the 1st quarter. Jane Street Group LLC now owns 31,198 shares of the company’s stock worth $174,000 after buying an additional 11,198 shares during the period. 95.05% of the stock is owned by institutional investors and hedge funds.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.